Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

DISEASE CHARACTERISTICS: * Histologically or CSF cytologically confirmed CNS lymphoma with any of the following clinical histories: * Primary CNS lymphoma at initial diagnosis * Primary CNS lymphoma at relapse * Systemic lymphoma with CNS disease at initial diagnosis or at relapse * Adequate fresh tissue or cell pellet available for analysis by Genitope Corporation to determine adequacy for idiotype (Id) manufacturing * Tumor must express both functional light and heavy chain genes * No tumors known or found to be surface immunoglobulin negative * Not in leukemic phase (i.e., \> 5,000/mm³ circulating tumor cells) PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100% * WBC ≥ 1,500/mm³ * Platelet count ≥ 75,000/mm³ * Hemoglobin ≥ 10 g/dL * Serum bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Gilbert's disease) * Creatinine ≤ 1.5 times ULN * Able to undergo placement of an Ommaya reservoir * Able to receive induction therapy (chemotherapy with or without brain radiotherapy) with intent to induce remission * Speaks English or Spanish * No other malignancy within the past 3 years, except adequately treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ * Not pregnant or nursing * No immunosuppressive viral infections as evidenced by HIV antibody or antigen, hepatitis B antigen, or hepatitis C antibody or antigen positivity * No history of autoimmune disease that required treatment within the…